ライフサイエンスコーパス: BCG vaccine

1 succumbed within eight weeks to conventional BCG vaccine.

2 the partially effective Mycobacterium bovis BCG vaccine.

3 er if the volunteers had previously received BCG vaccine.

4 ntion of TB disease compared to the standard BCG vaccine.

5 bovine tuberculosis (bTB), cross-react with BCG vaccine.

6 erlooked contributors to poorer responses to BCG vaccine.

7 tter than the suboptimal Mycobacterium bovis BCG vaccine.

8 culosis than the currently utilized M. bovis BCG vaccine.

9 t levels comparable to protection induced by BCG vaccine.

10 licensed vaccines, including live attenuated BCG vaccine.

11 quivalent to that of the Mycobacterium bovis BCG vaccine.

12 unized with conventional Mycobacterium bovis BCG vaccine.

13 , and positive controls received one dose of BCG vaccine.

14 ks, reductions similar to those generated by BCG vaccine.

15 ogy than animals immunized with the parental BCG vaccines.

16 beta-glucan or the Bacillus Calmette-Guerin (BCG) vaccine.

17 tillation with the bacillus Calmette-Guerin (BCG) vaccine.

18 antigen-containing bacillus Calmette-Guerin (BCG) vaccine.

19 caused by the live Bacillus Calmette-Guerin (BCG) vaccine.

20 e than the present bacillus Calmette-Guerin (BCG) vaccine.

21 ($136 per DALY) were similar to that of the BCG vaccine ($51.86-220.39 per DALY).

22 es (67.5%; 95% CI 60.5-73.8) and highest for BCG vaccine (92.7%: 95% CI 88.1-95.6).

23 ella vaccine/tick-borne encephalitis vaccine/BCG vaccine: adjusted hazard ratio [HR], 0.66 [95% CI, 0

24 luate the efficacy and immunogenicity of the BCG vaccine against high dose aerosol Mycobacterium tube

25 We compared the protective efficacy of the BCG vaccine against M tuberculosis infection with that a

26 8 participants we found no protection by the BCG vaccine against TST conversion regardless of cutoff

27 Although Bacillus Calmette-Guerin (BCG) vaccines against tuberculosis have been available f

28 burden at 16 weeks post-challenge while the BCG vaccine alone did not confer significant protection

29 ously received the bacillus Calmette-Guerin (BCG) vaccine; among this vaccinated group, the rate of p

30 rified protein derivative (PPD) with M bovis BCG vaccine and environmental mycobacteria.

31 In the BCG vaccine and placebo groups, 51 and 48 individuals, r

32 nd 138 cases per 100 000 person-years in the BCG vaccine and placebo groups, respectively, for an est

33 erculosis, C57BL/6 mice were vaccinated with BCG vaccine and then challenged 2 months later with one

34 Animals immunized with the recombinant BCG vaccines and challenged by aerosol with a highly vir

35 t also weakly virulent mycobacteria, such as BCG vaccines and environmental mycobacteria.

36 species, including Bacillus Calmette-Guerin (BCG) vaccines and environmental mycobacteria.

37 ts underwent randomization; 918 received the BCG vaccine, and 917 received placebo.

38 the efficacy of the bacille Calmette-Guerin (BCG) vaccine, and to uncover targets for novel antituber

39 BCG vaccines are given to more than 100 million children

40 00 million doses of bacille Calmette-Guerin (BCG) vaccine are given each year to protect against tube

41 Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine are multifaceted and poorly understood.

42 We enrolled 92 infants: 50 had received BCG vaccine at birth and 42 at 6 weeks of age.

43 e provide strong evidence that receiving the BCG vaccine at birth does not have a protective effect a

44 Infants delivered at home receive BCG vaccine at their first healthcare facility visit at

45 cines against the new virus, among which the BCG vaccine (Bacillus Calmette-Guerin) receives the most

46 ells in adults who have already received the BCG vaccine, but aerosol delivery of this vaccine might

47 We demonstrate that BCG vaccine can be dried without traditional freezing an

48 uggesting that a single dose of an effective BCG vaccine can have a long duration of protection.

49 Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine can confer protection against fatal forms o

50 Bacille Calmette-Guerin (BCG) vaccine can elicit good T(H)1 responses in neonates

51 Bacille Calmette-Guerin (BCG) vaccine could play a role in counteracting the risi

52 s immunized with their parental conventional BCG vaccine counterparts.

53 , a model in which parenterally administered BCG vaccine does not protect against tuberculosis.

54 e observe a notable protective effect of the BCG vaccine during the early stage of the pandemic.

55 In this trial, BCG vaccine efficacy persisted for 50 to 60 years, sugge

56 f the Th1 and Th17 cell lineages may improve BCG vaccine efficacy.

57 as a spray-dried nanomicroparticle aerosol, BCG vaccine exhibited high-efficiency delivery and perip

58 fectiveness of the Bacillus Calmette-Guerin (BCG) vaccine for prevention of Mycobacterium tuberculosi

59 he live attenuated bacillus Calmette-Guerin (BCG) vaccine for the prevention of disease associated wi

60 ding the use of the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis vary greatly throughout th

61 local reactogenicity, EPD of OVA/LPS/CpG and BCG vaccine generated a comparable humoral immune respon

62 Data from 1483 participants in the BCG vaccine group and 1309 in the placebo group were ana

63 as observed in 62 of 871 participants in the BCG-vaccine group and 59 of 849 participants in the plac

64 verse events occurred more frequently in the BCG-vaccine group than in the placebo group, and most we

65 opsy, animals immunized with the recombinant BCG vaccines had fewer and smaller lesions in the lung,

66 Moreover, BCG vaccine has been hypothesized to reduce the risk of

67 Although the BCG vaccine has been one of the most widely used vaccine

68 BCG vaccine has shown consistently high efficacy against

69 al priming with the Bacille Calmette-Guerin (BCG) vaccine has been associated with reduced offspring

70 ear even though the bacille Calmette Guerin (BCG) vaccine has been available for more than 75 years.

71 The bacille Calmette-Guerin (BCG) vaccine has immunomodulatory "off-target" effects t

72 utic agents and the bacille Calmette-Guerin (BCG) vaccine have not significantly affected the current

73 We therefore assessed the immunogenicity of BCG vaccine in HIV-exposed infants who received BCG at b

74 tive children, the safety of live attenuated BCG vaccine in HIV-positive adults remains unknown and a

75 g approach for enhancing the efficacy of the BCG vaccine in humans.

76 potential adjunct to the Mycobacterium bovis BCG vaccine in the mouse and guinea pig models of this d

77 pared pulmonary and subcutaneous delivery of BCG vaccine in the tuberculosis-susceptible DBA/2 mouse

78 To obviate potential adverse affects of BCG vaccines in immunodeficient individuals, we have stu

79 avenue is with the bacille-calmette-guerin (BCG) vaccine in autoimmune type 1 diabetes (T1D).

80 ins) may be resistant to Mycobacterium bovis BCG vaccine-induced antituberculosis protective immunity

81 axillary lymph node, indicating significant BCG vaccine-induced immune activation.

82 and population heterogeneity may affect the BCG vaccine-induced T-cell response.

83 ycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine-induced protection was lost in the absence

84 (strain H37Rv) and bacillus Calmette-Guerin (BCG) vaccine inhibit phagosome maturation in macrophages

85 d immunity approaching that conferred by the BCG vaccine is a feasible goal.

86 In tuberculosis-endemic regions, BCG vaccine is administered soon after birth, before in

87 pecific beneficial effects, and intravesical BCG vaccine is currently the recommended treatment for n

88 As the current BCG vaccine is derived from pathogenic mycobacteria, a s

89 The BCG vaccine is given to millions of children globally bu

90 The BCG vaccine is ineffective against adult tuberculosis.

91 duration of protection from tuberculosis of BCG vaccines is not known.

92 ycobacterium bovis Bacillus Calmette-Guerin (BCG) vaccine is administered parenterally to infants and

93 Bacillus Calmette-Guerin (BCG) vaccine is the most widely administered vaccine in

94 Although the Bacille-Calmette-Guerin (BCG) vaccine is used to prevent tuberculosis, it also of

95 Bacillus Calmette-Guerin (BCG) vaccine is widely used for the prevention of tuberc

96 Although the bacillus Calmette-Guerin (BCG) vaccine is widely used, it has major limitations as

97 d local side effects of LPS/CpG adjuvant and BCG vaccine, leading to complete skin recovery.

98 The tuberculosis BCG vaccine may provide heterologous protection against

99 ple, the live attenuated measles vaccine and BCG vaccine may reduce mortality from infections other t

100 BCG vaccine may reduce overall mortality by increasing r

101 This small study indicates that maternal BCG vaccine might be associated with reduced all-cause N

102 y volunteers received either live attenuated BCG vaccine (n = 20) or placebo (n = 20) in a randomized

103 maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy.

104 ho had undergone randomization, received the BCG vaccine or placebo, and had a negative QFT test 10 w

105 er adults to intracutaneous vaccination with BCG vaccine or placebo.

106 negative QFT test 10 weeks after receipt of BCG vaccine or placebo; the last criterion was added to

107 assigned newborn rhesus macaques to receive BCG vaccine or remain unvaccinated and then undergo oral

108 nfected with either bacille Calmette-Guerin (BCG) vaccine or virulent M. tuberculosis (77 and 35 days

109 Viability of BCG vaccine packaged in the caves and the mechanical str

110 ontacts, but not among 5644 adolescents, the BCG vaccine protected against QuantiFERON conversion at

111 Randomized trials assessing BCG vaccine protection against tuberculosis have widely

112 BCG vaccine protects against serious pediatric forms of

113 Little is known about how long the BCG vaccine protects against tuberculosis.

114 The bacillus Calmette-Guerin (BCG) vaccine protects against tuberculosis and heterolog

115 Mycobacterium bovis BCG vaccine provides only partial protection, and the sk

116 The Bacillus Calmette - Guerin (BCG) vaccine provides a critical but limited defense aga

117 The Bacillus Calmette-Guerin (BCG) vaccine provides protection against tuberculosis (T

118 lives per year, and improved efficacy of the BCG vaccine remains a World Health Organization priority

119 hlorophenyl)ethylene] reduces 6-month infant BCG vaccine response.

120 Overall, 62% of mothers (903 of 1451) had a BCG vaccine scar.

121 BCG vaccine scarring often is used as a surrogate marker

122 Thus, we found that, in older patients, BCG vaccine scarring was not associated with M. tubercul

123 Participants in both groups received the BCG vaccine (Serum Institute of India, Pune, India) at w

124 nts were vaccinated with the live parenteral BCG vaccine (Serum Institute of India, Pune, India) at w

125 Importantly, both ID91 + GLA-SE and BCG vaccines significantly reduced pulmonary bacterial b

126 nd Tice, we have constructed two recombinant BCG vaccines stably expressing and secreting the 30-kDa

127 o immune responses, even after adjusting for BCG vaccine strain and age at vaccination.

128 Current data on which BCG vaccine strain induces the optimal immune response i

129 Previous studies suggest that BCG vaccine strain influences the immune response and pr

130 ch has been developed to replace the current BCG vaccine strain, and modified vaccinia virus Ankara (

131 The attenuated bacillus Calmette-Guerin (BCG) vaccine strain is derived from a virulent strain of

132 f the M. bovis bacillus Calmette and Guerin (BCG) vaccine strain selected for an M. bovis PK+ mutant,

133 randomized to vaccination with one of three BCG vaccine strains (BCG-Denmark, BCG-Japan, or BCG-Russ

134 More than 20 genetically distinct BCG vaccine strains are in use worldwide.

135 Three commonly used Mycobacterium bovis BCG vaccine strains elicited different magnitudes of T-c

136 in the immune response induced by different BCG vaccine strains in newborn infants.

137 al were immunized at birth with one of three BCG vaccine strains.

138 d phenotypic variation between commonly used BCG vaccine strains.

139 in mice, we employed a combined anti-IL-10R1/BCG vaccine strategy.

140 Among patients who had not received the BCG vaccine, the rate of positivity by TST was 5.0% (62

141 nt evidence on the duration of protection by BCG vaccine, the screening of migrants and hard-to-reach

142 ased ability of the wild-type as well as the BCG vaccine to induce protective immunity.

143 included a 15-year follow-up of individuals (BCG vaccine treated or controls) whose condition did not

144 tients aged 70 years or older at the time of BCG vaccine treatment (HR, 0.74; 95% CI, 0.60-0.91).

145 tween 1987 and 2021, 3388 patients underwent BCG vaccine treatment (mean [SD] age, 69.89 [9.28] years

146 ves who participated in a placebo-controlled BCG vaccine trial during 1935-1938 and who were still at

147 During 1986-1989, a bacille Calmette-Guerin (BCG) vaccine trial was carried out in northern Malawi.

148 studied comprised Bacillus Calmette-Guerin (BCG) vaccine, Triple vaccine, Hepatitis B vaccine (HBV),

149 The BCG vaccine-used worldwide to prevent tuberculosis-confe

150 d ratio for a sustained QFT test conversion (BCG vaccine vs. placebo) was 1.04 (95% CI, 0.73 to 1.48)

151 Treatment with BCG vaccine was associated with a lower rate of ADRD (HR

152 In competing risks analysis, BCG vaccine was associated with a lower risk of ADRD (5-

153 RCTs: From 2 studies, early vaccination with BCG vaccine was associated with a reduced risk of eczema

154 In this study, BCG vaccine was associated with a significantly lower ra

155 t patterns of T-cell induction occurred when BCG vaccine was given at birth and at 6 weeks of age.

156 response induced by live Mycobacterium bovis BCG vaccine was greater than the response induced by any

157 ologous tumor cell-bacillus Calmette-Guerin (BCG) vaccine was conducted to determine whether surgical

158 y and to potentially improve efficacy of the BCG vaccine, we used CRISPRi to inhibit expression of th

159 All participants received the BCG vaccine (week 0); yellow fever (YF-17D), oral typhoi

160 tent than the current commercially available BCG vaccines, which were developed nearly a century ago.

161 The Bacillus Calmette-Guerin (BCG) vaccine, which has been used for > 100 years to pre